Fig. 2
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Maintenance phase Markov model. CDAI Crohn’s Disease Activity Index
Fig. 2 | Cost Effectiveness and Resource Allocation
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Maintenance phase Markov model. CDAI Crohn’s Disease Activity Index